Zacks Research Analysts Increase Earnings Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Investment analysts at Zacks Research raised their Q2 2025 earnings per share (EPS) estimates for Teva Pharmaceutical Industries in a research note issued to investors on Wednesday, April 17th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.57 per share for the quarter, up from their previous forecast of $0.56. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.28 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q1 2026 earnings at $0.53 EPS and FY2026 earnings at $2.70 EPS.

Several other analysts have also recently issued reports on TEVA. Jefferies Financial Group raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and increased their target price for the company from $10.00 to $14.00 in a research report on Tuesday, January 23rd. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Thursday, February 1st. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 price objective on the stock in a research report on Friday, March 8th. The Goldman Sachs Group increased their target price on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a "neutral" rating in a research report on Monday, February 5th. Finally, Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an "overweight" rating in a report on Monday, February 5th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $13.78.

Teva Pharmaceutical Industries Stock Down 3.0 %

Shares of NYSE TEVA traded down $0.40 during midday trading on Thursday, reaching $12.78. 8,956,290 shares of the company's stock traded hands, compared to its average volume of 10,686,016. The company has a market cap of $14.33 billion, a price-to-earnings ratio of -28.06, a P/E/G ratio of 1.57 and a beta of 1.05. Teva Pharmaceutical Industries has a one year low of $7.09 and a one year high of $14.47. The company has a quick ratio of 0.69, a current ratio of 1.02 and a debt-to-equity ratio of 2.23. The stock's 50 day simple moving average is $13.47 and its 200-day simple moving average is $11.22.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.25. The company had revenue of $4.46 billion for the quarter, compared to analysts' expectations of $3.97 billion. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 100,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the sale, the executive vice president now owns 382,590 shares of the company's stock, valued at approximately $5,172,616.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 31,766 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the sale, the chief accounting officer now directly owns 10,676 shares of the company's stock, valued at approximately $132,062.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mark Sabag sold 100,000 shares of the company's stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total value of $1,352,000.00. Following the completion of the sale, the executive vice president now owns 382,590 shares in the company, valued at approximately $5,172,616.80. The disclosure for this sale can be found here. Insiders have sold a total of 390,738 shares of company stock valued at $5,132,766 in the last ninety days. Company insiders own 0.62% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Assenagon Asset Management S.A. lifted its stake in shares of Teva Pharmaceutical Industries by 705.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 579,562 shares of the company's stock valued at $6,051,000 after purchasing an additional 507,568 shares during the period. Los Angeles Capital Management LLC purchased a new position in Teva Pharmaceutical Industries in the third quarter valued at $3,000,000. SG Americas Securities LLC raised its position in shares of Teva Pharmaceutical Industries by 31.7% in the fourth quarter. SG Americas Securities LLC now owns 544,878 shares of the company's stock worth $5,689,000 after acquiring an additional 131,043 shares during the period. Wellington Management Group LLP boosted its stake in shares of Teva Pharmaceutical Industries by 42.2% during the 3rd quarter. Wellington Management Group LLP now owns 344,587 shares of the company's stock worth $3,515,000 after acquiring an additional 102,261 shares in the last quarter. Finally, Gateway Investment Advisers LLC grew its position in shares of Teva Pharmaceutical Industries by 28.6% during the 4th quarter. Gateway Investment Advisers LLC now owns 41,882 shares of the company's stock valued at $437,000 after acquiring an additional 9,312 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.